Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TUCATINIB CONTINUATION PROTOCOL
NCT07768358Phase 4Not yet recruiting
- Sponsor
- Pfizer
- Start
- Nov 2026
- Primary completion
- Mar 2032
01
Overview
A Phase 4 trial of tucatinib in breast cancer, Cervical Cancer (CC), biliary neoplasm, urothelial carcinoma (UC), non-small cell lung cancer (NSCLC), sponsored by Pfizer. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
tucatinib
03
Conditions
breast cancerCervical Cancer (CC)biliary neoplasmurothelial carcinoma (UC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07768358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07768358.